BIOMARKERS FOR DIAGNOSIS, PREDICTION, ASSESSMENT AND STRATIFICATION OF FAINTING THERAPY Russian patent published in 2017 - IPC G01N33/68 

FIELD: medicine, pharmacy.

SUBSTANCE: this invention refers to the method for stratification of fainting treatment by determination of CT-proET-1 level in a sample fluid of the patient's body, correlation of CT-proET-1 level with fainting therapy stratification, for which the patients are stratified according to their need in a pacemaker by determination of CT-proET-1 level. The level above the predetermined threshold is indicative of patients with orthostatic hypotension, who do not need a pacemaker, and the level below the predetermined threshold is indicative of patients with cardio inhibiting reflex, who need a pacemaker. The predetermined threshold is between 30 and 70 pmol/l, where the sample is taken at baseline before the start of the orthostatic stability test, preferably HUT test or active getting up test. The invention also refers to CT-proET-1 level application for fainting therapy stratification.

EFFECT: invention provides stratification of fainting therapy for a patient.

15 cl, 1 tbl, 12 dwg